Wrap Text
Form S-3 – registration statement
ASP ISOTOPES INC.
(Incorporated in the State of Delaware,
United States of America)
(Delaware file number 6228898)
Ticker Symbol: NASDAQ: ASPI
ISIN: US00218A1051
LEI: 6488WHV94BZ496OZ3219
JSE Share Code: ISO
("ASPI" or "the Company")
FORM S-3 – REGISTRATION STATEMENT
Pursuant to the Securities Act of 1933, ASPI stockholders are advised that a Form S-3 registration
statement, which includes a prospectus that covers the offering, issuance and sale by ASPI of up to $250.0
million in the aggregate of its common stock, preferred stock, debt securities, warrants, and/or units, in each
case from time to time in one or more offerings, has been filed with the U.S. Securities and Exchange
Commission.
We may from time to time offer and sell any securities described in this prospectus, either individually or in
combination with other securities, in one or more offerings of up to $250.0 million in aggregate initial offering
price.
This prospectus provides a general description of the securities we may offer. We will provide the specific
terms of the securities offered in one or more supplements to this prospectus. The prospectus supplements
will also describe the specific manner in which these securities will be offered. We may also authorize one
or more free writing prospectuses to be provided to you in connection with these offerings. The prospectus
supplement and any related free writing prospectus may add, update or change information contained in
this prospectus. Please read carefully this prospectus, the applicable prospectus supplement, any related
free writing prospectus, and the documents incorporated by reference before you invest in any of our
securities. This prospectus may not be used to offer or sell any securities unless accompanied by the
applicable prospectus supplement.
Our common stock is listed on the Nasdaq Capital Market ("Nasdaq") under the symbol "ASPI." On October
13, 2025, the last reported sale price of our common stock was $13.32 per share. The applicable prospectus
supplement will contain information, where applicable, as to any other listing on Nasdaq or any securities
market or other exchange of the securities, if any, covered by the prospectus supplement.
Investing in our securities involves a high degree of risk. See "Risk Factors" on page 4 of this prospectus
and in the documents incorporated by reference into this prospectus, as updated by the applicable
prospectus supplement, any related free writing prospectus and other future filings we make with the
Securities and Exchange Commission that are incorporated by reference into this prospectus, for a
discussion of the factors we urge you to consider carefully before deciding to purchase our securities.
We may sell these securities directly to investors, through agents designated from time to time or to or
through underwriters or dealers. For additional information on the methods of sale, please see the section
titled "Plan of Distribution" in this prospectus. If any underwriters are involved in the sale of any securities
with respect to which this prospectus is being delivered, the names of such underwriters and any applicable
commissions or discounts will be set forth in a prospectus supplement. The price to the public of such
securities and the net proceeds we expect to receive from such sale will also be set forth in a prospectus
supplement.
Neither the Securities and Exchange Commission nor any state securities commission has approved or
disapproved of these securities or determined if this prospectus is truthful or complete. Any representation
to the contrary is a criminal offense.
A copy of the Form S-3, including full details of the prospectus, can be found at:
https://www.sec.gov/Archives/edgar/data/1921865/000147793225007536/aspi_s3asr.htm
15 October 2025
Sponsor
Valeo Capital Proprietary Limited
Date: 15-10-2025 07:08:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
Sharenet Sites 
